License and Collaboration Agreements (Tables) (Sanofi [Member])

9 Months Ended

Sep. 30, 2014

Sanofi [Member]

Schedule of Revenue Recognized and Assets and Liabilities under Collaborative Arrangements

During the three and nine months ended September 30, 2014 and 2013, the Company recognized revenue based on the following components of the Sanofi Agreement:

	Three months ended September 30,				Nine months ended September 30,
(in thousands)	2014		2013		2014		2013
Upfront payment	$	13,415	$	1,250	$	27,933	$	3,750
Milestone payments		5,590		521		11,639		1,562
Development services		2,953		4,521		16,694		30,794
Manufacturing services and other		6,044		564		12,585		3,304
Total	$	28,002	$	6,856	$	68,851	$	39,410

As of September 30, 2014 and December 31, 2013, the Company maintained the following assets and liabilities related to the Sanofi Agreement:

(in thousands)	September 30, 2014		December 31, 2013
Accounts receivable, billed	$	1,387	$	2,357
Accounts receivable, unbilled		302		3,417
Deferred revenue		21,236		73,392